Bio-Rad Laboratories Inc header image

Bio-Rad Laboratories Inc

BIO

Equity

ISIN null / Valor 912793

New York Stock Exchange, Inc (2026-10-06)
USD 368.83-2.89%

Bio-Rad Laboratories Inc
UMushroom community rating:

star star star star star
4.50 2 votes No rating yet
NegativeNeutralPositive

About company

Bio-Rad Laboratories Inc. is a global leader in the development and manufacturing of innovative products for the life science research and clinical diagnostics markets. The company provides a wide range of tools and services that facilitate scientific discovery and improve healthcare outcomes. Bio-Rad's offerings include instruments, software, consumables, reagents, and content for the areas of cell biology, gene expression, protein purification, and imaging, among others. In the clinical diagnostics sector, Bio-Rad supplies products that support laboratory quality control, including specialty immunoassay analyte measurements such as procalcitonin, active vitamin B12, interleukin-6, and fructosamine. These products are complemented by QCNet, a platform for peer group result comparison, enhancing the accuracy and reliability of diagnostic testing. With a strong emphasis on innovation and quality, Bio-Rad serves a diverse customer base, including academic institutions, biotechnology companies, and healthcare providers worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

19.3%1Y
3.38%3Y
-49.0%5Y

Performance

37.4%1Y
37.9%3Y
37.8%5Y

Volatility

Market cap

7995 M

Market cap (USD)

Daily traded volume (Shares)

162,539

Daily traded volume (Shares)

1 day high/low

328.13 / 326.34

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

2 votes
Performance:
starstarstarstarstar
4.50
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
5.00
Georgi Arabadjiev
Switzerland, 04 Feb 2021
star star star star star
More biochemical developments
Georgi Arabadjiev
Switzerland, 19 Jan 2021
star star star star star

EQUITIES OF THE SAME SECTOR

IQVIA Holdings Inc
IQVIA Holdings Inc IQVIA Holdings Inc Valor: 39103858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.30%USD 259.98
Arvinas Inc
Arvinas Inc Arvinas Inc Valor: 43526042
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.01%USD 7.31
AstraZeneca PLC
AstraZeneca PLC AstraZeneca PLC Valor: 982352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.65%GBP 119.58
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1103058
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.70%GBP 10.12
Envista Holdings Corporation
Envista Holdings Corporation Envista Holdings Corporation Valor: 49153522
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.30%USD 23.27
Humana Inc
Humana Inc Humana Inc Valor: 940174
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.05%USD 404.27
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.60%GBP 16.20
Indivior PLC
Indivior PLC Indivior PLC Valor: 121550831
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.67%GBP 27.04
Beximco Pharmaceuticals Ltd
Beximco Pharmaceuticals Ltd Beximco Pharmaceuticals Ltd Valor: 2318407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 0.54
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.93%EUR 70.30